Adrenal involvement in the antiphospholipid syndrome
- Outcome of primary antiphospholipid syndrome in childhood. Gattorno, M.; Falcini, F.; Ravelli, A.; Zulian, F.; Buoncompagni, A.; Martini, G.; Resti, M.; Picco, P.; Martini, A. // Lupus;2003, Vol. 12 Issue 6, p449
The objective of this paper is to investigate the long-term outcome of primary antiphospholipid syndrome (APS) in the paediatric age. The features of unselected patients with primary APS who had disease onset before the age of 16 years were retrospectively analysed in three Italian referral...
- Antiphospholipid Antibodies and Management of Pregnancy. Sadovsky, Richard // American Family Physician;3/1/1997, Vol. 55 Issue 4, p1422
Discusses the treatment cited for antiphospholipid antibody syndrome. What the condition means; Details of a study conducted on the condition; Why obstetric implications of positive test results are uncertain; Affects on pregnant women; Conclusions made on the results of study.
- ï¿½2GP-I in the anti phospholipid (Hughes') syndromeï¿½from a cofactor to an autoantigen ï¿½ from induction to prevention of antiphospholipid syndrome. Shoenfeld, Y.; Gharavi, A.; Koike, T. // Lupus;1998, Vol. 7 Issue 8, p503
Focuses on the relationship between the Hughes' syndrome and serum glycoprotein (Beta2GP-I). Prevention of anti-phospholipid (APS ) by an oral tolerance with Beta2GP-I; Infectious etiology of APS.
- [Anti-ï¿½[sub 2] Glycoprotein Iï¿½ï¿½[sub 2] Glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. Biasiolo, A.; Rampazzo, P.; Brocco, T.; Barbero, F.; Rosato, A.; Pengo, V. // Lupus;1999, Vol. 8 Issue 2, p121
Antiphospholipid syndrome (APS) is defined by the presence of aPL antibodies in patients with thromboembolic phenomena. Some antiphospholipid (aPL) antibodies, such as those directed against ï¿½[sub 2]-glycoprotein I (ï¿½[sub 2]GPI), are associated with thromboembolism, possess Lupus...
- Erythema nodosum associated with antiphospholipid antibodies: a report of three cases. Nekhlyudov, L.; Gradzka, M.; Conti-Kelly, A.M.; Greco, T.P. // Lupus;2000, Vol. 9 Issue 8, p641
Erythema nodosum is a dermatologic condition characterized by painful, erythematous nodules on the anterior surfaces of the lower extremities. Its association with a variety of conditions has been previously described. We present three cases of erythema nodosum in patients with elevated...
- The BH1 idiotype defines a population of anticardiolipin antibodies closely associated with the antiphospholipid syndrome. Mason, A.N.; Harmer, I.J.; Mageed, R.A.; Mackworth-Young, C.G. // Lupus;1999, Vol. 8 Issue 3, p234
Background: A human IgM monoclonal anticardiolipin antibodyï¿½BH1ï¿½has previously been described, which has characteristics typical of antiphospholipid antibodies in the serum of patients with antiphospholipid syndrome (APS). It appears to be idiotypically distinct from other human...
- antiphospholipid antibody syndrome. // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p153
A definition of the medical term "antiphospholipid antibody syndrome" is presented, which refers to a medical condition characterized by hypercoagulability related with high blood levels of immunoglobulin G antibodies against phospholipids.
- Antiphospholipid antibody levels in intravenous immunoglobulin (IVIg) preparations. Sherer, Y; Wu, R; Krause, I; Peter, JB; Shoenfeld, Y // Lupus;Aug2001, Vol. 10 Issue 8, p568
The antiphospholipid syndrome (APS) is characterized by various clinical manifestations and by elevated levels of antiphospholipid antibodies. Passive induction of APS by infusion of these antibodies has been demonstrated in animal models. Intravenous immunoglobulin (IVIg) is one of the...
- Antiphospholipid syndrome: a consensus for treatment? Khamashta, Munther A; Shoenfeld, Phd Yehuda // Lupus;2003, Vol. 12 Issue 7, p495
Editorial. Comments on the management of antiphospholipid syndrome. Pathogenesis and clinical manifestations; Risk factors; Presence of antiphospholipid antibodies; Evidence-based medicine.